Dimming Brachytherapy's Glow?
Executive SummaryDisappointing clinical trial results have investors fleeing coronary-radiation leader Novoste, but is there more to the story?
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.